This research study is currently not recruiting patients.

An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects with Primary Biliary Cholangitis (PBC)

Brief description of study

The purpose of this research study is to measure the effectiveness and safety of seladelpar (MBX-8025) in treating persons with primary biliary cholangitis (PBC). This will be done by looking at how the study drug affects PBC. Seladelpar is an investigational drug. Investigational means that the drug has not been approved by US Food and Drug Administration (FDA). Human and animal studies have shown that seladelpar may be useful for treating the signs and symptoms of PBC as well as treating the signs and symptoms of lipid metabolism and familial hypercholesterolemia. PBC persons who have participated in other PBC studies with seladelpar will be invited to participate in this research study.


Clinical Study Identifier: s18-00560
ClinicalTrials.gov Identifier: NCT03301506